Gastrointestinal stromal tumor epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
Akshun Kalia (talk | contribs) No edit summary |
Akshun Kalia (talk | contribs) |
||
| Line 7: | Line 7: | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
===Incidence=== | ===Incidence=== | ||
*The incidence of gastrointestinal stromal tumors (GIST) is approximately 1.0-1.60 cases per 100,000 individuals worldwide. | *The incidence of gastrointestinal stromal tumors (GIST) is approximately 1.0-1.60 cases per 100,000 individuals worldwide.<ref name="pmid8000994">{{cite journal |vauthors=Thomas RM, Sobin LH |title=Gastrointestinal cancer |journal=Cancer |volume=75 |issue=1 Suppl |pages=154–70 |year=1995 |pmid=8000994 |doi= |url=}}</ref> | ||
*In United States, the annual incidence of GIST is approximately 1.54 cases per 100,000 individuals. Every year around 4000-5000 new cases of GIST are reported. | *In United States, the annual incidence of GIST is approximately 1.54 cases per 100,000 individuals. Every year around 4000-5000 new cases of GIST are reported. | ||
*The incidence of GIST in European nations is relatively similar to other countries. Population based studies have shown the following results: | *The incidence of GIST in European nations is relatively similar to other countries. Population based studies have shown the following results: | ||
| Line 18: | Line 18: | ||
===Prevalence=== | ===Prevalence=== | ||
*The prevalence of GIST is approximately 12.9 cases per 100,000 individuals worldwide. | *The prevalence of GIST is approximately 12.9 cases per 100,000 individuals worldwide.<ref name="pmid8000994">{{cite journal |vauthors=Thomas RM, Sobin LH |title=Gastrointestinal cancer |journal=Cancer |volume=75 |issue=1 Suppl |pages=154–70 |year=1995 |pmid=8000994 |doi= |url=}}</ref> | ||
*With the use of new tyrosine kinase inhibitors such as imatinib, the prevalence of GIST is estimated to go upto 31.8 cases per 100,0000 individuals. | *With the use of new tyrosine kinase inhibitors such as imatinib, the prevalence of GIST is estimated to go upto 31.8 cases per 100,0000 individuals.<ref name="NilssonBümming2005">{{cite journal|last1=Nilsson|first1=Bengt|last2=Bümming|first2=Per|last3=Meis-Kindblom|first3=Jeanne M.|last4=Odén|first4=Anders|last5=Dortok|first5=Aydin|last6=Gustavsson|first6=Bengt|last7=Sablinska|first7=Katarzyna|last8=Kindblom|first8=Lars-Gunnar|title=Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era|journal=Cancer|volume=103|issue=4|year=2005|pages=821–829|issn=0008543X|doi=10.1002/cncr.20862}}</ref> | ||
===Age=== | ===Age=== | ||
Revision as of 15:43, 15 December 2017
|
Gastrointestinal stromal tumor Microchapters |
|
Differentiating Gastrointestinal stromal tumor from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Gastrointestinal stromal tumor epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Gastrointestinal stromal tumor epidemiology and demographics |
|
FDA on Gastrointestinal stromal tumor epidemiology and demographics |
|
CDC on Gastrointestinal stromal tumor epidemiology and demographics |
|
Gastrointestinal stromal tumor epidemiology and demographics in the news |
|
Blogs on Gastrointestinal stromal tumor epidemiology and demographics |
|
Directions to Hospitals Treating Gastrointestinal stromal tumor |
|
Risk calculators and risk factors for Gastrointestinal stromal tumor epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Akshun Kalia M.B.B.S.[2]
Overview
Epidemiology and Demographics
Incidence
- The incidence of gastrointestinal stromal tumors (GIST) is approximately 1.0-1.60 cases per 100,000 individuals worldwide.[1]
- In United States, the annual incidence of GIST is approximately 1.54 cases per 100,000 individuals. Every year around 4000-5000 new cases of GIST are reported.
- The incidence of GIST in European nations is relatively similar to other countries. Population based studies have shown the following results:
- In Iceland, the annual incidence of GIST is approximately 1.2 cases per 100,000 individuals.
- In Sweden, the annual incidence of GIST is approximately 1.45 cases per 100,000 individuals.
- In Netherlands, the annual incidence of GIST is approximately 1.2 cases per 100,000 individuals.
- In Spain, the annual incidence of GIST is approximately 1.09 cases per 100,000 individuals.
- Recent studies have shown that the highest incidence of GIST have been reported in Hong Kong, Taiwan and northern Norway with an estimated 1.90-2.20 cases per 100,000 individuals.
Prevalence
- The prevalence of GIST is approximately 12.9 cases per 100,000 individuals worldwide.[1]
- With the use of new tyrosine kinase inhibitors such as imatinib, the prevalence of GIST is estimated to go upto 31.8 cases per 100,0000 individuals.[2]
Age
- Patients of all age groups may develop GIST.
- GIST commonly affects individuals older than 40 years of age with the median age of 60s.
- GIST is extremely rare in patients younger than 30 years of age.
Race
- A study based on Surveillance, Epidemiology and End Results (SEER) registry data found that GIST usually affects individuals of the white race (72.2%).
- The SEER study also concluded that Blacks and Hispanics individuals are less likely to develop GIST.[3]
Gender
- Males are more commonly affected by GIST than females.
- The male to female ratio is approximately 1.1 to 1.
Region
- The majority of GIST cases were reported in Hong Kong, Shanghai (China), Taiwan; and northern Norway, with a an estimated 19-22 cases per million per year.
References
- ↑ 1.0 1.1 Thomas RM, Sobin LH (1995). "Gastrointestinal cancer". Cancer. 75 (1 Suppl): 154–70. PMID 8000994.
- ↑ Nilsson, Bengt; Bümming, Per; Meis-Kindblom, Jeanne M.; Odén, Anders; Dortok, Aydin; Gustavsson, Bengt; Sablinska, Katarzyna; Kindblom, Lars-Gunnar (2005). "Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era". Cancer. 103 (4): 821–829. doi:10.1002/cncr.20862. ISSN 0008-543X.
- ↑ Cheung MC, Zhuge Y, Yang R, Koniaris LG (2009). "Disappearance of racial disparities in gastrointestinal stromal tumor outcomes". J. Am. Coll. Surg. 209 (1): 7–16. doi:10.1016/j.jamcollsurg.2009.03.018. PMID 19651058.